State of evidence on AMR
- Relatively poor information about geographical distribution and burden of AMR
- Multiple public and private sources of data – often not collated at the national and international levels
- Data collection often with little information on individual patients
- Fundamental issues of selection bias on who gets into hospital-based lab data systems
- Protocols for diagnostic methods and data collection not yet standardized
Project deliverables
- Gather and assemble global data on 17 bacteria-antibacterial drug combinations
- Develop methods to generate AMR/DRI burden estimates for the selected pathogen-drug combinations of international concern
- Provide results through a compelling interface for data visualization
Project scope and approach
We will prioritize estimating burden for 17 “bug-drug” combinations of international public health concern and priority for the WHO member states, as well as the Bill & Melinda Gates Foundation:
| Bacteria | Antibacterial drug(s) |
|---|---|
| Escherichia coli | Third-generation cephalosporins, fluoroquinolones |
| Shigella | Fluoroquinolones |
| Klebsiella pneumoniae | Third-generation cephalosporins, carbapenems |
| Streptococcus pneumoniae | Penicillin |
| Staphylococcus pneumoniae | Methicillin |
| Salmonella Typhi and Paratyphi | Fluoroquinolones, chloramphenicol |
| Non-typhoidal Salmonellae | Fluoroquinolones |
| Neisseria gonorrhoeae | Third-generation cephalosporins |
| Mycobacterium tuberculosis | First-line - isoniazid, rifampicin; Second-line - fluoroquinolones, amikacin, capreomycin, kanamycin |